The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 04, 2011
Filed:
Oct. 07, 2009
Dominique Louis Nestor Ghislain Surleraux, Machelen, BE;
Sandrine Marie Helene Vendeville, Brussels, BE;
Wim Gaston Verschueren, De Wittestraat, BE;
Marie-pierre T. M. M. G. DE Bethune, Twee Leeuwenstraat, BE;
Herman Augustinus DE Kock, Wolfseind, BE;
Abdellah Tahri, Heverlee, BE;
Dominique Louis Nestor Ghislain Surleraux, Machelen, BE;
Sandrine Marie Helene Vendeville, Brussels, BE;
Wim Gaston Verschueren, De Wittestraat, BE;
Marie-Pierre T. M. M. G. De Bethune, Twee Leeuwenstraat, BE;
Herman Augustinus De Kock, Wolfseind, BE;
Abdellah Tahri, Heverlee, BE;
Tibotec Pharmaceuticals Ltd, , IE;
Abstract
The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein Rand Reach are H, optionally substituted Calkyl, Calkenyl, Ccycloalkyl, aryl, Het, Het; Rmay also be a radical of formula (RR)NC(RR)CR—; t is 0, 1 or 2; Ris H or Calkyl; L is —C(═O)—, —O—C(═O)—, —NR—C(═O)—, —O—Calkanediyl-C(═O)—, —NR—Calkanediyl-C(═O)—, —S(═O)—, —O—S(═O)—, —NR—S(═O); Ris Calkyl, aryl, Ccycloalkyl, CcycloalkylCalkyl, or arylCalkyl; Ris H, CalkylOC(═O), carboxyl, aminoC(═O), mono- or di(Calkyl)aminoC(═O), Ccycloalkyl, Calkenyl, Calkynyl or optionally substituted Calkyl; Rand Rare H or Calkyl. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.